ANI Pharma (ANIP) Announces Proposed Stock Offering, Size not Disclosed

Go back to ANI Pharma (ANIP) Announces Proposed Stock Offering, Size not Disclosed

ANI Pharma (ANIP) Prices 1.5M Share IPO at $50/sh

November 4, 2021 5:36 AM EDT

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) today announced the pricing of an underwritten public offering of 1,500,000 shares of its common stock at a public offering price of $50.00 per share. The gross proceeds of the offering to the Company are expected to be $75 million, before deducting the underwriting discounts and commissions and other offering expenses. In addition, ANI granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

The... More

Truist Securities Starts ANI Pharmaceuticals (ANIP) at Buy

November 2, 2021 6:06 AM EDT

Truist Securities analyst Gregory Fraser initiates coverage on ANI Pharmaceuticals (NASDAQ: ANIP) with a Buy rating and a price target of $70.00.


For an analyst ratings summary and ratings history on ANI Pharmaceuticals click here. For more ratings news on ANI Pharmaceuticals click here.


Shares of ANI Pharmaceuticals closed at $55.89 yesterday.

... More

Pre-Open Stock Movers 11/01: (ANIP) (LDI) (HOG) Higher; (BTBT) (TRIP) (CRWD) Lower (more...)

November 1, 2021 9:29 AM EDT

Pre-Open Stock Movers:

Bit Digital, Inc. (NASDAQ: BTBT) 17% LOWER; gives back some of Friday's late-day surge.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) 15.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has approved the Companys supplemental New Drug Application (sNDA) for Purified Cortrophin Gel (Repository Corticotropin Injection USP) (Cortrophin Gel) for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (MS) and rheumatoid arthritis (RA), in addition to excess urinary protein due... More

ANI Pharma (ANIP) Reports Q3 Loss of $0.37/sh

November 1, 2021 6:48 AM EDT

ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of ($0.37), versus $0.04 reported last year. Revenue for the quarter came in at $52.1 million, versus $52.98 million reported last year.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

... More